Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

318 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bilateral breast metastases from ewing sarcoma of the femur.
Astudillo L, Lacroix-Triki M, Ferron G, Rolland F, Maisongrosse V, Chevreau C. Astudillo L, et al. Among authors: ferron g. Am J Clin Oncol. 2005 Feb;28(1):102-3. doi: 10.1097/01.coc.0000149741.46332.17. Am J Clin Oncol. 2005. PMID: 15685043
Prospective multicentric randomized study comparing periareolar and peritumoral injection of radiotracer and blue dye for the detection of sentinel lymph node in breast sparing procedures: FRANSENODE trial.
Rodier JF, Velten M, Wilt M, Martel P, Ferron G, Vaini-Elies V, Mignotte H, Brémond A, Classe JM, Dravet F, Routiot T, de Lara CT, Avril A, Lorimier G, Fondrinier E, Houvenaeghel G, Avigdor S. Rodier JF, et al. Among authors: ferron g. J Clin Oncol. 2007 Aug 20;25(24):3664-9. doi: 10.1200/JCO.2006.08.4228. Epub 2007 May 7. J Clin Oncol. 2007. PMID: 17485709 Clinical Trial.
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.
Azaïs H, Brochard C, Taly V, Benoit L, Ferron G, Ray-Coquard I, You B, Abadie-Lacourtoisie S, Lebreton C, Venat L, Louvet C, Favier L, Blonz C, Dohollou N, Malaurie E, Dubot C, Kurtz JE, Pujade-Lauraine E, Rouleau E, Leary A, Bats AS, Blons H, Laurent-Puig P. Azaïs H, et al. Among authors: ferron g. Gynecol Oncol. 2024 Dec 12;192:145-154. doi: 10.1016/j.ygyno.2024.12.004. Online ahead of print. Gynecol Oncol. 2024. PMID: 39671779 Free article.
The prognostic value of tumor-infiltrating lymphocytes in vulvovaginal melanoma.
Vanbockstael M, Bataillon G, Morisseau M, Ferron G, Attal J, Meresse T, Tournier E, Tanguy Le Gac Y, Pages C, Martinez A. Vanbockstael M, et al. Among authors: ferron g. Int J Gynecol Cancer. 2024 Dec 2;34(12):1853-1860. doi: 10.1136/ijgc-2024-005359. Int J Gynecol Cancer. 2024. PMID: 39566931
Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial.
Classe JM, Meeus P, Hudry D, Wernert R, Quenet F, Marchal F, Houvenaeghel G, Bats AS, Lecuru F, Ferron G, Brigand C, Berton D, Gladieff L, Joly F, Ray-Coquard I, Durand-Fontanier S, Liberale G, Pocard M, Georgeac C, Gouy S, Guilloit JM, Guyon F, Costan C, Rousselet JM, de Guerké L, Bakrin N, Brument E, Martin E, Asselain B, Campion L, Glehen O; UNICANCER/CHIPOR Investigators. Classe JM, et al. Among authors: ferron g. Lancet Oncol. 2024 Dec;25(12):1551-1562. doi: 10.1016/S1470-2045(24)00531-X. Epub 2024 Nov 14. Lancet Oncol. 2024. PMID: 39549720 Clinical Trial.
Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy.
Ferguson SE, Brotto LA, Kwon J, Samouelian V, Ferron G, Maulard A, Kroon C, Driel WV, Tidy J, Williamson K, Mahner S, Kommoss S, Goffin F, Tamussino K, Eyjolfsdottir B, Kim JW, Gleeson N, Tu D, Shepherd L, Plante M. Ferguson SE, et al. Among authors: ferron g. J Clin Oncol. 2024 Oct 1:JCO2400440. doi: 10.1200/JCO.24.00440. Online ahead of print. J Clin Oncol. 2024. PMID: 39353164 Free article.
Reproductive outcomes after fertility-sparing surgery for cervical cancer - results of the multicenter FERTISS study.
Fricová L, Kommoss S, Scambia G, Ferron G, Kocián R, Harter P, Anchora LP, Bats AS, Novàk Z, Walter CB, Raspagliesi F, Lambaudie E, Bahrehmand K, Andress J, Klát J, Pasternak J, Matylevich O, Szeterlak N, Minář L, Heitz F, Căpîlna ME, Runnebaum I, Cibula D, Sláma J. Fricová L, et al. Among authors: ferron g. Gynecol Oncol. 2024 Nov;190:179-185. doi: 10.1016/j.ygyno.2024.08.020. Epub 2024 Aug 28. Gynecol Oncol. 2024. PMID: 39197417
Advanced cytoreductive procedures: patient positioning and exposition maneuvers in 10 steps.
Luzarraga Aznar A, Bebia V, Acosta U, Bonaldo G, Sánchez-Iglesias JL, Pérez-Benavente A, Gil-Moreno A, Ferron G, Angeles MA. Luzarraga Aznar A, et al. Among authors: ferron g. Int J Gynecol Cancer. 2025 Jan 6:ijgc-2024-005886. doi: 10.1136/ijgc-2024-005886. Online ahead of print. Int J Gynecol Cancer. 2025. PMID: 39179253 No abstract available.
Outcomes of minimal residual disease at upfront debulking surgery compared with complete cytoreduction after neoadjuvant chemotherapy.
Romero V, Angeles MA, Rodríguez González E, Cabarrou B, Gil-Moreno A, Pérez-Benavente A, Spagnolo E, Guyon F, Babin G, Bebia V, Luzarraga Aznar A, Bataillon G, Bétrian S, Ferron G, Hernández A, Martinez A. Romero V, et al. Among authors: ferron g. Int J Gynecol Cancer. 2025 Jan 6:ijgc-2024-005692. doi: 10.1136/ijgc-2024-005692. Online ahead of print. Int J Gynecol Cancer. 2025. PMID: 39117375
318 results